Indoco Remedies Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
INDOCO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.2 pts less than Nifty Microcap 250 and 7.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Indoco Remedies Limited has submitted its financial results for the quarter and financial year ended March 31, 2025 to the stock exchange. This is a routine regulatory filing required under SEBI listing norms, typically accompanied by audited annual results and Q4 numbers. The actual financial figures, including revenue, profit, and margin details, would be available in the detailed results document filed with the exchange. Investors should refer to the full results PDF for specific performance metrics and management commentary.
This is a procedural compliance filing and does not by itself move the stock. The actual impact on shareholders will depend on the underlying numbers in the submitted results — particularly revenue growth, profit margins, and any forward guidance — which need to be reviewed separately.